The efficacy and safety of daclatasvir combined with asunprevir in the treatment of 26 cases with chronic hepatitis C

Abstract

Objective To explore the efficacy and safety of daclatasvir (DCV) combined with asunprevir (ASV) for chronic genotype 1b (GT1b) hepatitis C. Methods Twenty-nine GT1b hepatitis C patients who were treated with DCV combined ASV in Henan Provincial People′s Hospital from September 2017 to November 2017 were included. Hepatitis C virus (HCV) RNA levels were tested before treatment, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after treatment, and 12 weeks after the end of the treatment. The comorbidities, combined use of drugs and adverse clinical events were registered. T test was used to compare the measurement data with normal distribution and M (P25, P75) was used for measurement data with non-normal distribution. Results A total of 29 patients with GT1b were included, with 4 cirrhosis cases and 25 non cirrhotic cases. Seven patients had history of previous interferon and ribavirin combination treatment. There were 9 patients with comorbidity and 7 patients with combined medication. Finally, 25 patients completed a 24-week course of antiviral treatment; 3 patients were lost to follow-up, and 1 patient withdrew after 16weeks of antiviral treatment because of a virus rebound. Of the 26 followed up patients, 25 achieved sustained virological response at 12-week (SVR12), and one patient failed. And the HCV RNA NS5A resistance-associated variants (RAV) were detected in the patients with treatment failure. No severe adverse clinical events occurred in 26 patients. Conclusions DCV combined with ASV is effective and safe in the treatment of GT1b chronic hepatitis C. However, the effect of RAV on therapeutic efficacy should be concerned during the treatment. Key words: Hepatitis C, chronic; Daclatasvir; Asunprevir